Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 19/20 | 0.57 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26264786 | 0.93 | TLR4 (0.57) | TLR4LY96TLR2 | |
| SCHEMBL3930073 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3937496 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3939045 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3928509 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3938094 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL7502609 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3925341 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL3928902 | 0.91 | TLR4 (0.69) | TLR4LY96 | |
| SCHEMBL26263929 | 0.90 | TLR4 (0.56) | TLR4LY96TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521762-B1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7960523-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080033155-A1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-7288640-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-7232900-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | CORIXA CORPORATION (US) | 2007-06-19 | — | — | US | disclosed |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040267007-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | CORIXA CORPORATION | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267007-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor | DDOST, STT3A, STT3B | TLR4 609/4885LY96 394/4885TLR2 858/4885 |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | DDOST, AGL, GALE | TLR4 661/4885LY96 372/4885TLR2 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.